Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Bassendine, M.F.; Nielsen, S.U.; Bridge, S.H.; Felmlee, D.J.; Sheridan, D.A.; Packard, C.J.; Neely, R.D. (2017)
Publisher: Elsevier
Languages: English
Types: Article
Subjects: A300, C500
Hepatitis C virus (HCV) is a major pathogen with approximately 3% of the world's population (over 170 million) infected. Epidemiological studies have shown HCV is associated with an increased risk of cardiovascular and cerebrovascular mortality as well as peripheral arterial disease. This is despite HCV inducing an ostensibly favourable lipid profile with accompanying low classical risk score for atherosclerosis (AS). We discuss possible factors involved in the aetiopathogenesis of atherosclerosis in chronic HCV and hypothesise that an important mechanism underlying the development of AS is the presence of circulating low-density immune complexes that induce an inflammatory response. We suggest that HCV particles may be inducing an antibody response to lipoproteins present in the lipoviral particles and sub-viral particles – a concept similar to the more general ‘autoantibody’ response to modified LDL. After virologic cure some AS risk factors will recede but an increase in serum cholesterol could result in progression of early atherosclerotic lesions, leaving a legacy from persistent HCV infection that has clinical and therapeutic implications.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol 2013;61(5):511-23.
    • [2] Campbell LA, Rosenfeld ME. Infection and atherosclerosis development. Arch Med Res 2015;46(5):339-50.
    • [3] Ji YN, An L, Zhan P, Chen XH. Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. Mol Biol Rep 2012;39(6):6537-46.
    • [4] Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet 2014;384(9943):607-17.
    • [5] Kostis WJ. How low an LDL-C should we go with statin therapy? Curr Atheroscler Rep 2014;16(2):388.
    • [6] Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Lipids and HCV. Semin Immunopathol 2013;35(1):87-100.
    • [7] Paul D, Madan V, Bartenschlager R. Hepatitis C virus RNA replication and assembly: living on the fat of the land. Cell Host Microbe 2014;16(5):569-79.
    • [8] Ampuero J, Romero-Gomez M. Assessing cardiovascular risk in hepatitis C: an unmet need. World J Hepatol 2015;7(19):2214-9.
    • [9] Vassalle C, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004;90(5):565-6.
    • [10] Roed T, Lebech AM, Kjaer A, Weis N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging 2012;32(6):421-30.
    • [11] Maruyama S, Koda M, Oyake N, Sato H, Fujii Y, Horie Y, et al. Myocardial injury in patients with chronic hepatitis C infection. J Hepatol 2013;58(1):11-5.
    • [12] Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010;59(8):1135-40.
    • [13] Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012;221(2):496-502.
    • [14] Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 2010;47(1):72-5.
    • [15] Olubamwo OO, Onyeka IN, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C as a risk factor for carotid atherosclerosis - a systematic review. Clin Physiol Funct Imaging 2016;36: 249-60.
    • [16] He H, Kang R, Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS ONE 2013;8(11):e81305.
    • [17] Huang H, Kang R, Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and metaanalysis. PLOS ONE 2014;9(9):e106376.
    • [18] Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014;61(1 Suppl):S69-78.
    • [19] Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008;167(6):743-50.
    • [20] Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009;49(2):225-32.
    • [21] Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011;4(4):425-32.
    • [22] Lin MS, Guo SE, Chen MY, Huang TJ, Huang JC, Hu JH, et al. The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram. Am J Med Sci 2014;347(6):478-84.
    • [23] Pothineni NV, Delongchamp R, Vallurupalli S, Ding Z, Dai Y, Hagedorn CH, et al. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. Am J Cardiol 2014;114(12):1841-5.
    • [24] Chew KW, Bhattacharya D, McGinnis K, Horwich TB, Tseng CH, Currier J, et al. Coronary heart disease risk by Framingham risk score in hepatitis C and HIV/hepatitis C coinfected persons. AIDS Res Hum Retroviruses 2015;31:718-22.
    • [25] Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010;41(12):2894-900.
    • [26] Hsu YH, Muo CH, Liu CY, Tsai WC, Hsu CC, Sung FC, et al. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol 2015;62(3):519-25.
    • [27] Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290(7):898-904.
    • [28] Bielinski SJ, Berardi C, Decker PA, Kirsch PS, Larson NB, Pankow JS, et al. P-selectin and subclinical and clinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2015;240(1):3-9.
    • [29] Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, et al. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 2012;142(3):634-43.
    • [30] Roed T, Kristoffersen US, Knudsen A, Wiinberg N, Lebech AM, Almdal T, et al. Increased prevalence of coronary artery disease risk markers in patients with chronic hepatitis C--a crosssectional study. Vasc Health Risk Manag 2014;10:55-62.
    • [31] Ferroni P, Mammarella A, Martini F, Paoletti V, Cardarello CM, Labbadia G, et al. Increased soluble P-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load. J Investig Med 2001;49(5):407-12.
    • [32] Satoh K, Nagano T, Seki N, Tomita Y, Aida Y, Sugita T, et al. High level of serum cholesteryl ester transfer protein in active hepatitis C virus infection. World J Hepatol 2016;8(5):291-300.
    • [33] Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition is not yet dead-pro. Arterioscler Thromb Vasc Biol 2016;36(3):439-41.
    • [34] Nicholls SJ, Ruotolo G, Brewer HB, Wang MD, Liu L, Willey MB, et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol 2016;10(3):519-27.
    • [35] McLain JH, Alsterda AJ, Arora RR. Cholesteryl ester transfer protein inhibitors: trials and tribulations. J Cardiovasc Pharmacol Ther 2016;(August), pii:1074248416662349.
    • [36] Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009;29(Suppl 2):13-25.
    • [37] Schnier C, Wild S, Kurdi Z, Povey C, Goldberg DJ, Hutchinson SJ. Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection. J Viral Hepat 2016;23:596-605.
    • [38] Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxi A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 2016;150(1):145-55.
    • [39] Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, et al. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clin Mol Hepatol 2014;20(1):38-46.
    • [40] Economou EK, Oikonomou E, Siasos G, Papageorgiou N, Tsalamandris S, Mourouzis K, et al. The role of microRNAs in coronary artery disease: from pathophysiology to diagnosis and treatment. Atherosclerosis 2015;241(2):624-33.
    • [41] Lee CH, Kim JH, Lee SW. The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol 2014;52(6):445-51.
    • [42] Willeit P, Skroblin P, Kiechl S, Fernandez-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur Heart J 2016.
    • [43] Zhou L, Irani S, Sirwi A, Hussain MM. MicroRNAs regulating apolipoprotein B-containing lipoprotein production. Biochim Biophys Acta 2016.
    • [44] van der Meer AJ, Farid WR, Sonneveld MJ, de Ruiter PE, Boonstra A, van Vuuren AJ, et al. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 2013;20(3):158-66.
    • [45] van der Ree MH, van der Meer AJ, van Nuenen AC, de Bruijne J, Ottosen S, Janssen HL, et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment Pharmacol Ther 2016;43(1):102-13.
    • [46] Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res 2014;114(11): 1743-56.
    • [47] Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb 2013;20(10):743-54.
    • [48] Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006;27(2):134-9.
    • [49] Sobenin IA, Salonen JT, Zhelankin AV, Melnichenko AA, Kaikkonen J, Bobryshev YV, et al. Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value. Biomed Res Int 2014;2014:205697.
    • [50] Nilsson J, Bjorkbacka H, Fredrikson GN. Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential. Curr Opin Lipidol 2012;23(5):422-8.
    • [51] Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and verylow-density hepatitis C virus RNA-containing particles. J Virol 2002;76(14):6919-28.
    • [52] Scholtes C, Ramiere C, Rainteau D, Perrin-Cocon L, Wolf C, Humbert L, et al. High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology 2012;56(1):39-48.
    • [53] Agnello V, Abel G. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 1997;40(11):2007-15.
    • [54] Woollard KJ. Immunological aspects of atherosclerosis. Clin Sci (Lond) 2013;125(5):221-35.
    • [55] Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013;13(10): 709-21.
    • [56] Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 1988;168(3):1041-59.
    • [57] Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012;55(4):998-1007.
    • [58] Roque-Cuellar MC, Sanchez B, Garcia-Lozano JR, GarridoSerrano A, Sayago M, Praena-Fernandez JM, et al. Expression of CD81, SR-BI and LDLR in lymphocytes and monocytes from patients with classic and occult hepatitis C virus infection. J Med Virol 2012;84(11):1727-36.
    • [59] Harwood NM, Golden-Mason L, Cheng L, Rosen HR, Mengshol JA. HCV-infected cells and differentiation increase monocyte immunoregulatory galectin-9 production. J Leukoc Biol 2016;99(3):495-503.
    • [60] Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis 2015;15:19.
    • [61] Olubamwo OO, Aregbesola AO, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C and risk of coronary atherosclerosis - a systematic review. Public Health 2016;138:12-25.
    • [62] Manigold T, Shin EC, Mizukoshi E, Mihalik K, Murthy KK, Rice CM, et al. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 2006;107(11):4424-32.
    • [63] Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 2015;61(3): 790-801.
    • [64] Horl G, Froehlich H, Ferstl U, Ledinski G, Binder J, Cvirn G, et al. Simvastatin efficiently lowers small LDL-IgG immune complex levels: a therapeutic quality beyond the lipid-lowering effect. PLOS ONE 2016;11(2):e0148210.
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
  • No similar publications.

Share - Bookmark

Cite this article